Læknaneminn - 01.10.1991, Page 92

Muller, F., Wassle, H., og Voigt, T.; Pharmacological
modulation of the rod pathway in the cat retina. Journal of
Neurophysiology,59,6, 1657-1672, 1988.
Nilsson, S.E.G., og Andersson, B.E.; Corneal D.C.
recordings of slow ocular potential changes such as the ERG
c-wave and the light peak in clinical work: equipment and
examples of results. Documenta Ophthalmologica, 68,313-
325,1988.
Noble, K.G. og Carr, R.E.: Stargardt's disease and fundus
flavimaculatus. Archives of Ophthalmology, 97, 1281-
1285, 1979.
Noell,W.K.;Theoriginoftheelectroretinogram. American
Journal ofOphthalmology, 38,78-90. 1954.
Oakley, B., og Green, D.G.; Correlation of light-induced
changes in retinal extracellular potassium concentration
with c-wave of the electroretinogram. Journal of
Neurophysiology, 39, 1117-1133, 1976.
Peachey, N.S., Fishman, G.A., Derlacki, D.J., og Brigell,
M.G., Psychophysical and electroretinographic findings in
x-linkedjuvenileretinoschisis. Archives of Ophthalmology,
105,513, 1987.
Peachey, N.S., Alexander, K.R., Fishman, G.A., Derlacki,
D.J.; Properties of the human cone system
electroretinogram during light adaptation. Applied Optics,
28,6, 1145-1150, 1989.
Riggs, L.A.: Continuous and reproducible records of the
electrical activity og the human retina. Proceedings of the
Society for experimental biology and medicine., 48, 204,
1941.
Slaughter, M.M., og Miller, R.F.; 2-antino-4-
phosphonobutyric acid: a new pharmacological tool for
retina research. Science, 221, 182-185, 1981.
Slaughter, M.M., og Miller, R.F.; An excitatory amino acid
antagonist blocks cone input to sign-conserving second
order retinal neurons. Science, 219, 1230-1232, 1983.
Stockton, R.A., og Slaughter, M.M.: B-wave of the
electroretinogram: a reflection of ON bipolar cell activity.
Journal ofGeneral Physiology, 93, 101-122, 1989.
Yanoff, M., Rahn, E.H, og Zimmerman, L.E.;
Histopathology of juvenile retinoschisis. Archives of
ophthalmology, 79,49, 1968.
Wakabayashi, K., Yonemura, D., og Kawasaki, K.:
Electrophysiological analysis of Stargardt's disease fundus
flavimaculatus. Documenta Ophthalmologica, 60, 141-
147,1985.
Witkovsky, P., Stone, S., og Ripps, H.; Pharmacological
modification of the light-induced responses of Muller (glial)
cells in the amphibian retina. Brain Research, 32,111 -120,
1985.
VERUCID® GETUR
EYTT VÖRTUM OG SIGGI
FÆST í NÆSTU LYFJABÚÐ
ÁN LYFSEÐILS
FRAMLEIÐANDI: pHarma - medica A/S
DREIFING: FARMASÍA H.F.
P.O. BOX 5460 - REYKJAVÍK - SÍMI 91-626622
VERUCID (pHarma medica,
782295)
ÁBURÐUR; D 11 AF
1 g inniheldur: Acidum
salicylicum 110 mg, Acidum
lacticum 40 mg, Cupri acetas,
samsvarandi Cu + + 11 míkróg,
Collodium 8% 762,5 mg,
Colophonium 20 mg.
HLAUP; D 11 A F
1 g inniheldur: Acidum
salicylicum 100 mg, Acidum
lacticum 40 mg, Colophonium
20 mg, Collocium 8% 762,5 mg,
Cupri acetas, samsvarandi 11
mikróg Cu t +.
Eiglnleikar: Lyf, sem heíur
ætandi og horhhúöarleysandi
(keratólýtiska) verkun.
Ábendingar: Vörtur, likþorn og
sigg.
Frábendlngar: Brúnar vörtur og
fæðingarblettir.
Varúð: Ætandi lyf, sem ekki má
bera á slimhúð og ekki má
berast í augu, nef eða munn.
Skammtar: Berist á i þunnu lagi
tvisvar á dag og látið þorna í
nokkrar mínútur.
Pakknlngar: Áburöur: 10 ml.
Hlaup: 5 g.
Hverri pakkningu lyfsíns skal
fylgja leiöarvísir á íslensku
meö leiöbelningum um notkun
þess og varnaöarorö.